Manufacturer
BRISTOL-MYERS SQUIBB S.R.L.
Contents
Nivolumab
Indication
As monotherapy or in combination w/ ipilimumab for advanced (unresectable or metastatic) melanoma in adults. As monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults. As monotherapy for advanced renal cell carcinoma after prior therapy in adults. As monotherapy for relapsed or refractory classical Hodgkin's lymphoma after autologous stem cell transplant (ASCT) & treatment w/ brentuximab vedotin in adults. As monotherapy for squamous cell cancer of the head & neck in adults progressing on or after platinum-based therapy. As monotherapy for locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.
Instruction
Monotherapy 3 mg/kg over 60 min IV every 2 wk. In combination w/ ipilimumab 1 mg/kg administered as an IV infusion over 60 min every 3 wk for the first 4 doses in combination w/ 3 mg/kg ipilimumab administered IV over 90 min. Then, followed by 3 mg/kg nivolumab administered as an IV infusion over 60 min every 2 wk. 1st dose of nivolumab monotherapy should be administered 3 wk following the last dose of nivolumab & ipilimumab combination.
Drug interaction
Potential interference w/ pharmacodynamic activity may occur w/ systemic corticosteroids & other immunosuppressants at baseline before starting therapy.
Malaysia
